close read more
Press release

Servier opts for Saclay as its future Research Centre


Servier opts for Saclay as its future Research Centre

4 October 2017 Construction of the future Servier Research Centre, covering an area of around 45,000m2, is to be entrusted to Wilmotte et Associés and should be completed in 2021 at the Paris Saclay campus.

With 25% of its turnover (excluding generic products) re-invested in R&D every year, the Servier Group has always given pride of place to research.

The decision to establish its future Research Centre at the Paris Saclay campus, near the Ecole Normale Paris Saclay (formerly ENS Cachan), the Ecole Polytechnique and the Pôle Biologie-Chimie-Pharmacie de l’Université de Paris-Sud, is confirmation of this policy.

As a result, activities at the Group’s existing research centres at Croissy, Suresnes and in the Orléans region will be brought together at a single site. Eventually, around 600 Servier researchers will be employed at the site, which has the capacity to accommodate up to around 800 people.

Olivier Laureau, President of the Servier Group, has underlined the Group’s commitment to research: “Our future Research Centre is fully in line with the strategic ambition of the Group, namely to be a key player in innovative healthcare. We are choosing Saclay because we believe in the potential of France to ensure the success of this ecosystem on an international scale.”

A real multidisciplinary platform, the aim of the building will be to embody the values of the Group, in particular team spirit, collaboration and openness, in an environment that encourages the expression of ideas and talents. This investment of almost 260 million euros will also make it possible for researchers to interact with many other stakeholders in healthcare in order to ensure that the patient is always at the heart of research programmes.

This flagship project for Servier is also in tune with the urban campus landscaped by the Paris-Saclay Development Authority (Etablissement Public d’Aménagement Paris-Saclay).

Claude Bertrand, Managing Director, R&D, added: “By envisaging Research 4.0, today the Group is looking ahead in order to anticipate the challenges faced by generations to consider healthcare from a global perspective, with the patient at its heart.”

Designed in close collaboration with the Wilmotte et Associés architect’s office, the style of the building will also comprise a unifying circle, an entrance door for everyone which will allow employees to mingle throughout the day in order to exchange ideas in a constructive and open spirit. There will also be laboratories, project rooms and a ‘project hotel’ to accommodate start-ups and innovative projects, both French and international. The building is designed to be as flexible and adaptable as possible in order to ensure that it is able to keep pace with future technological and scientific developments, all against a strong ecological background.

Emmanuel Canet, Executive Vice-President in charge of R&D, concluded: “Servier has always decided in favour of developing a high-performance research facility. The planned establishment at Saclay is going to stimulate this research even further, enabling us to evolve within one of the world’s leading centres, with skills and expertise drawn from around the globe.”

This Project forms part of the Opération d’intérêt national (operation of national interest)


About the Paris-Saclay Development Authority

The vocation of the Paris-Saclay Development Authority, created under the 2010 “Greater Paris” Act, is to drive and coordinate “the development of the Paris-Saclay scientific and technological cluster and the promotion of its international scope and outreach”. The authority acts as the developer for the joint development zones located within the scope of the Operation of National Interest.

The Urban campus operational project is today underway with:

– More than 220,000 m² of delivered projects (EDF Lab, the Lieu de Vie community building, the Orsay Institute of Molecular Science, Nanoscience and nanotechnology center, CentraleSupelec, ENSAE ParisTech, the Civil Aviation Radar…).

– 287,180 m² of construction sites with works in progress or in their launch phase (Ecole Normale Supérieure Paris-Saclay, Sports facilities, Institut Mines-Télécom, students and family housing…)

– Consultations underway for 200,000 m2 of developments: the Central innovating urban program, Shared Teaching Building, Palaiseau’s Subprefecture, Pharmaco-Biology-Chemistry research and teaching cluster at Université Paris-Sud, the Business Incubator & Serviced Office Centre…).

– Studies underway and financing secured for 185 060 m2 of developments (Learning Center, local sports facilities, AgroParisTech / INRA etc.).


About Servier

Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 148 countries and a turnover of 4 billion euros in 2016, Servier employs 21,000 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generic drugs) in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neuropsychiatric disease, oncology and diabetes, as well as by its activities in high-quality generic drugs.

More information: www.servier.com


 Press Contact

Karine Bousseau Servier External Communications

Tel: +33 1 5572 4021 /+33



Agence Manifeste pour l’EPA Paris-Saclay


+33 6 08 35 88 89


Press release

Last press release

Press release
Servier appoints Angelo Paci as Oncology & Immuno-Oncology Program Leader
Press release
Servier appoints Nicolas Lévy as Chief Scientist Rare Diseases
Press release
Appointment of Walid S. Kamoun, PhD. MSc., Global Head of Servier R&D Oncology